Email this article 
Options of modeling diet-induced and combined metabolic syndrome
- Authors: Abramtsova A.V.1, Efimenko N.V.1, Reps V.F.1, Kaisinova A.S.1
-
Affiliations:
- Pyatigorsk Scientific Research Institute of Resort Study — a branch of the North Caucasian Federal Scientific Clinical Centre of the Federal Medical and Biology Agency
- Issue: Vol 19, No 6 (2020)
- Pages: 346-354
- Section: Original studies
- URL: https://rjpbr.com/1681-3456/article/view/78544
- DOI: https://doi.org/10.17816/1681-3456-2020-19-6-1
- ID: 78544
Cite item
Open Access
Access granted
Abstract
Background. Due to the fact that it is not always possible to reproduce all known manifestations of carbohydrate and lipid metabolism disorders, for example, in rodents, it is necessary to verify individual pathogenetic links in animals when modeling the metabolic syndrome in order to select the most optimal natural biotropic factors for studying the effect on them.
Aims: To analyze metabolic disorders in the modeling of metabolic syndrome of alimentary genesis in comparison with the combined effect of alimentary factor and chemical agents to select the most appropriate model in the study of natural and weak preformed physical factors.
Materials and methods. Metabolic syndrome was modeled in 47 sexually mature outbred white male rats using a hypercaloric diet (HD) of various duration and medications. The first series was the 1st control group (CG1) and the 1st experimental group (EG1). They received HD during 180 days, they were withdrawn from the experiment 30 days after the cancellation of HD. The second series was the 2nd control group (CG2) and three experimental groups. They received HD for 60 days, where the 2nd group (EG2) in association with HD received Mercazolil (10 mg/kg of animal weight) intragastrically for 14 days starting from the 21st day; the 3rd group (EG3) had the same scheme of treatment as in EG2, besides, after taking Mercazolil, they were intramuscularly injected with Nitox 200 at 25 mg/kg once per day during 5 days. Animals of EG2 and EG3 were withdrawn from the experiment 60 days after ending of HD. Animals of the 4th experimental group (EG4) got HD and the same medicine as in EG3. They left the experiment 30 days after ending HD. The content of hormones and biochemical parameters of protein, fat, and carbohydrate in peripheral blood was evaluated using multiple inter-group comparisons and intra-group relationships by Spearman’s rank correlation method.
Results. There have been detected a large number of biochemical signs of dependence of metabolism regulation on leptin level after long-term HD (180 days), while there were fewer biochemical signs of protein exchange disorder less than with the combined use of HD (60 days) and drugs.
Conclusion. It is more appropriate and promising to use a long-term HD as a model of MS close to the natural conditions of its formation, to study the influence of natural and weak preformed physical factors.
Keywords
Full Text
About the authors
Anna V. Abramtsova
Pyatigorsk Scientific Research Institute of Resort Study — a branch of the North Caucasian Federal Scientific Clinical Centre of the Federal Medical and Biology Agency
Author for correspondence.
Email: abramtsovaav@ngs.ru
ORCID iD: 0000-0001-7435-6286
SPIN-code: 9608-8004
MD, Cand. Sci. (Med.)
Russian Federation, PyatigorskNatalia V. Efimenko
Pyatigorsk Scientific Research Institute of Resort Study — a branch of the North Caucasian Federal Scientific Clinical Centre of the Federal Medical and Biology Agency
Email: abramtsovaav@ngs.ru
ORCID iD: 0000-0001-7005-8927
SPIN-code: 8041-7520
MD, Dr. Sci. (Med.), Professor
Russian Federation, PyatigorskValentina F. Reps
Pyatigorsk Scientific Research Institute of Resort Study — a branch of the North Caucasian Federal Scientific Clinical Centre of the Federal Medical and Biology Agency
Email: abramtsovaav@ngs.ru
ORCID iD: 0000-0003-4878-6797
SPIN-code: 4556-1046
Dr. Sci. (Biol.)
Russian Federation, PyatigorskAgnessa S. Kaisinova
Pyatigorsk Scientific Research Institute of Resort Study — a branch of the North Caucasian Federal Scientific Clinical Centre of the Federal Medical and Biology Agency
Email: abramtsovaav@ngs.ru
ORCID iD: 0000-0003-1199-3303
SPIN-code: 6552-9684
MD, Dr. Sci. (Med.), Professor
Russian Federation, PyatigorskReferences
- Uchamprina VA, Romantseva TI, Kalashnikova MF. Metabolic syndrome: arguments "for" and "against". Obesity and Metabolism. 2012;(2):17–27. (In Russ.)
- Recommendations for the management of patients with metabolic syndrome: clinical recommendations. Moscow; 2013. 42 p. Available from: https://mzdrav.rk.gov.ru/file/mzdrav_18042014_Klinicheskie_rekomendacii_Metabolicheskij_sindrom.pdf (In Russ.)
- Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbid pathology in clinical practice. Algorithms of diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5–66. (In Russ.)
- Karaman YK, Lobanova EG, Novgorodtseva TP. The Role of signaling molecules in the mechanisms of development of multiple organ pathology with alimentary dyslipidemia. Byulleten' RAMN. 2010;30(1):59–63. (In Russ.)
- Turmova EP. Atherosclerosis: immunogenetic and metabolic links of pathogenesis (clinical and experimental study) [dissertation abstract]. Chelyabinsk; 2015. 42 p. (In Russ.)
- Alicka M, Major P, Wysocki M, Adipose-Derived KM. Mesenchymal stem cells isolated from patients with type 2 diabetes show reduced "Stemness" through an altered secretome profile, enhanced anti-oxidative protection, and mitochondrial dynamics determination. J Clin Med. 2019;8(6):765. doi: 10.3390/jcm8060765
- Kovarenko MA, Ruyatkina LA, Petrishcheva MS, et al. Leptin: physiological and pathological aspects of action. Bulletin of the NSU. Biology series. 2003;1(1):59–74. (In Russ.)
- Leshchenko DV, Kostyuk NV, Belyakova MB, et al. Leptin-deficient and leptin-resistant rodent lines as models of metabolic syndrome. Modern Problems of Science and Education. 2015;(4) [Electronic resource]. Available from: http://science-education.ru/ru/article/view?id=20974 (In Russ.)
- Romantsova TI, Volkova GE. Leptin and ghrelin: antagonism and interaction in the regulation of energy metabolism. Obesity and Metabolism. 2005;(2):2–10. (In Russ.)
- Kryuchkova ON, Shahbazidi D, Shahbazidi G. Leptin — a key link in the pathogenesis of obesity. Crimean Therapeutic Journal. 2012;(1):33–36. (In Russ.)
- Dedov II, Melnichenko GA, Butrova SA. Adipose tissue as an endocrine organ. Obesity and Metabolism. 2006;(1):13–17. (In Russ.)
- Petrova NV. Leptin gene-a marker of cell therapy of metabolic syndrome. Biomedicine. 2019;15(3):12–22. (In Russ.)
- Dzhioeva AS. Evaluation of the effectiveness of restorative treatment of patients with arterial hypertension by studying the dynamics of cytokine activity. Cytokines and Inflammation. 2010;9(4):78–79. (In Russ.)
- Efimenko NI, Chala EN, Kasinova AS. Medical rehabilitation of patients with metabolic syndrome with different periods of treatment at the Spa. Doctor. 2017;(1):21–27. (In Russ.)
- Botvineva LA, Kaisinova AS, Fedorova TE, et al. Potable mineral waters in the restorative treatment of patients with metabolic syndrome. Russian Journal of the Physial Therapy, Balneotherapy and Rehabilitation. 2018;17(1):15–18. (In Russ.)
- Abramtsova AV, Efimenko NV, Reps VF, Soprun DS. Theoretical justification of the correction of the metabolic syndrome by natural mineral waters in the perspective of experimental research. Resort Medicine. 2017;(1):16–19. (In Russ.)
- Efimenko NV, Kaisinova AS, Fedorova TE, Botvineva LA. Efficiency of resort therapy with the use of drinking mineral waters of the Essentuki type in the treatment of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Voprosy balneologii, fizioterapii i lechebnoy fizicheskoy kultury. 2015;(3):14–17. (In Russ.)
- Kravchuk EN, Galagudza MM. Experimental models of metabolic syndrome. Arterial Hypertension. 2011;20(5):377–383. (In Russ.)
- Bueverov AO, Bogomolov PO, Bueverova EL. Hepatotoxicity of antibacterial drugs in therapeutic practice. Clin Microbiol Antimicrobial Chemotherapy. 2015;17(3):207–216. (In Russ.)
- Kamilov FKh, Ganeev TI, Kozlov VN, et al. The choice of the method of administration and dose of thiamazole for modeling hypothyroidism in laboratory rats. Biomedicine. 2008;(1):59–70. (In Russ.)
- Patent RUS No. 2500041. Grigoryuk AA, Turmova EP, Markelova EV. A method for modeling atherosclerosis. Available from: https://rusneb.ru/catalog/000224_000128_0002500041_20131127_C1_RU/ (In Russ.)
- Patent RUS No. 2598351 C1. Arishidze DA, Kozlova MA, Semin IA. A method for modeling non-alcoholic steatohepatitis in rats. Available from: https://yandex.ru/patents/doc/RU2598351C1_20160920 (In Russ.)
- Patent RUS No. 2453002. Karaman YuK, Novgorodtseva TP, Gvozdenko TA, et al. A method for modeling multiple organ pathology in rats. Available from: https://yandex.ru/patents/doc/RU2453002C1_20120610 (In Russ.)
Supplementary files
